Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
156.93
+0.34 (0.22%)
Nov 20, 2026, 10:00 AM EST - Market open
Neurocrine Biosciences Employees
Neurocrine Biosciences had 2,500 employees as of September 30, 2026. The number of employees increased by 700 or 38.89% compared to the same quarter last year. That makes Neurocrine Biosciences the 9,003rd largest employer in the world and 1,557th in the United States.
Employees
2,500
Change (1Y)
700
Growth (1Y)
38.89%
Revenue / Employee
$1,480,680
Profits / Employee
$281,000
Market Cap
15.88B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 2,500 | 700 | 38.89% |
| Dec 31, 2025 | 2,000 | 200 | 11.11% |
| Dec 31, 2024 | 1,800 | 400 | 28.57% |
| Dec 31, 2023 | 1,400 | 200 | 16.67% |
| Dec 31, 2022 | 1,200 | 300 | 33.33% |
| Dec 31, 2021 | 900 | 55 | 6.51% |
| Dec 31, 2020 | 845 | 145 | 20.71% |
| Dec 31, 2019 | 700 | 115 | 19.66% |
| Dec 31, 2018 | 585 | 185 | 46.25% |
| Dec 31, 2017 | 400 | 204 | 104.08% |
| Dec 31, 2016 | 196 | 76 | 63.33% |
| Dec 31, 2015 | 120 | 26 | 27.66% |
| Dec 31, 2014 | 94 | 13 | 16.05% |
| Dec 31, 2013 | 81 | 3 | 3.85% |
| Dec 31, 2012 | 78 | 7 | 9.86% |
| Dec 31, 2011 | 71 | 5 | 7.58% |
| Dec 31, 2010 | 66 | 1 | 1.54% |
| Dec 31, 2009 | 65 | -60 | -48.00% |
| Dec 31, 2008 | 125 | -10 | -7.41% |
| Dec 31, 2007 | 135 | -132 | -49.44% |
| Dec 31, 2006 | 267 | -321 | -54.59% |
| Dec 31, 2005 | 588 | 203 | 52.73% |
| Dec 31, 2004 | 385 | 40 | 11.59% |
| Dec 31, 2003 | 345 | 69 | 25.00% |
| Dec 31, 2002 | 276 | 54 | 24.32% |
| Dec 31, 2001 | 222 | 34 | 18.09% |
| Dec 31, 2000 | 188 | 37 | 24.50% |
| Dec 31, 1999 | 151 | 2 | 1.34% |
| Dec 31, 1998 | 149 | 41 | 37.96% |
| Dec 31, 1997 | 108 | 5 | 4.85% |
| Dec 31, 1996 | 103 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,527 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Alkermes | 2,050 |
| United Therapeutics | 1,400 |
NBIX News
- 2 days ago - Neurocrine Biosciences Transcript: Jefferies Global Healthcare Conference - Transcripts
- 7 days ago - Neurocrine price target raised to $191 from $185 at Morgan Stanley - TheFly
- 9 days ago - Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference - PRNewsWire
- 15 days ago - Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules - PRNewsWire
- 16 days ago - Neurocrine price target raised to $224 from $207 at Guggenheim - TheFly
- 16 days ago - Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress - PRNewsWire
- 16 days ago - Neurocrine rises 14.9% - TheFly
- 17 days ago - Neurocrine price target raised to $175 from $165 at Deutsche Bank - TheFly